Franziska Schenk

Franziska Schenk

Auto-generated profile, based on publicly available information

Franziska Schenk

Research Group Gene Modification in Stem Cells, Division of Veterinary Medicine, Paul-Ehrlich-Institute, 63225 Langen, Germany

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 October 2022 in Cell Reports
Verified
Journal Article
Open access
MRMarcel G.E. Rommel
Marcel G.E. Rommel
LWLisa Walz
Lisa Walz
FFFoteini Fotopoulou
Foteini Fotopoulou
SKSaskia Kohlscheen
Saskia Kohlscheen
FSFranziska Schenk
Franziska Schenk
UMUte Modlich
Ute Modlich
Respiratory tract infections are among the deadliest communicable diseases worldwide. Severe cases of viral lung infections are often associated with a cytokine storm and alternating platelet numbers. We report that hematopoietic stem and progenitor cells (HSPCs) sense a non-systemic influenza A virus (IAV) infection via inflammatory cytokines. Irrespective of antiviral treatment or vaccination, at a certain threshold of IAV titer in the lung, CD41-positive hematopoietic stem cells (HSCs) enter the cell cycle while endothelial protein C receptor-positive CD41-negative HSCs remain quiescent. Active CD41-positive HSCs represent the source of megakaryocytes, while their multi-lineage reconstitution potential is reduced. This emergency megakaryopoiesis is thrombopoietin independent and attenuated in IAV-infected interleukin-1 receptor-deficient mice. Newly produced platelets during IAV infection are immature and hyper-reactive. After viral clearance, HSC quiescence is re-established. Our study reveals that non-systemic viral respiratory infection has an acute impact on HSCs via inflammatory cytokines to counteract IAV-induced thrombocytopenia.

3 January 2022 in Molecular Therapy Nucleic Acids
Verified
Journal Article
Open access
VWVanessa M.A. Woods
Vanessa M.A. Woods
LLLisette J. Latorre-Rey
Lisette J. Latorre-Rey
FSFranziska Schenk
Franziska Schenk
MRMarcel G.E. Rommel
Marcel G.E. Rommel
TMThomas Moritz
Thomas Moritz
UMUte Modlich
Ute Modlich
Platelets are anucleate blood cells that are shed from megakaryocytes (MKs) into the bloodstream to maintain hemostasis and promote wound healing after vascular injury. To carry out their functions, platelets become activated and release bioactive substances from their secretory granules. As alpha granules (αGs) in resting platelets store proteins and release them only after activation, the packaging of proteins into αGs is an attractive strategy to deliver therapeutic proteins. Here, we propose an adjustable model for targeting transgenic proteins to platelet αGs using third-generation self-inactivating lentiviral vectors. The vectors express from the murine platelet factor 4 promoter (mPf4P), restricting transgene expression to the MK lineage. For the delivery and retention of expressed proteins in αGs, proteins are fused to short peptide sorting signals derived from the human cytokine RANTES or from the transmembrane protein P-selectin. We demonstrate effective targeting of GFP to αGs of murine and human in vitro-differentiated MKs and murine platelets in vivo. Furthermore, interferon-α (IFNα), as a potentially therapeutic cytokine, was successfully delivered to and stored in murine platelets in vivo, was released after activation, and inhibited virus replication in vitro. Our vectors create possibilities for numerous applications in cell therapy utilizing platelets as carriers of therapeutic proteins.